IN HYPOPHOSPHATASIA (HPP), DEFICIENT ALP can ruin bones, bodies, and lives. Alexion Endocrinology, Diabetes & Metabolism Case Reports

ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P162 

The effect of testesterone replacement therapy on HDL subfraction levels in hypogonadotropic hypogonadism

Abdullah Taslipinar1, Y Alper Sonmez1, Erol Bolu1, Serkan Tapan2, Gokhan Uckaya1, Aydogan Aydogdu1 & Mustafa Kutlu1

Author affiliations

The high-density lipoprotein (HDL) levels are decreased in paitents with hypogonadotropic hypogonadism (HH). Although testosteron regulates lipoprotein metabolism, the effect of testosterone replacement therapy on HDL metabolism is not clearly shown in HH. The aim of this study is to determine the effects of testesterone replacement on HDL subfractions in young patients with HH. Forty-three cases with HH (mean age 21±2.45 years) were enrolled. Fifty-one healthy volunteer matched for age and BMI were enrolled as controls. All patients were treated with testosterone esthers (250 mg, IM in every 3 weeks for 3 months) both before and after treatment. HDL subfractions HDL2 and HDL3 were measured by precipitation with polyethylene glygol (PEG). Serum samples were treated with precipitation reagent ‘Quantolip’. Total HDL, HDL2 and HDL3 levels of the patients and controls were not statistically different before the treatment. Sixteen of the 43 cases patients finished the therapy and the remaining are still under treatment. Total HDL and HDL2 levels after therapy did not change significantly. However, the HDL3 subfraction reduced significantly following testosterone replacement (P=0.02). In this study, we observed that young men with HH did not have significant HDL profile alterations compared to eugonadal men matched for age and BMI. Although the HDL3 subfraction was reduced after the testosterone replacement, HDL3 subfraction is not reported to have a major role in the antherosclerothic process. Thus, the role of testosterone treatment on the atherosclerothic process is not expected to be related to the alterations in HDL subfractions.

This Issue/Conference

Article tools

My recent searches